References
- US Food & Drug Administration (FDA). Vfend, Summary of Product Characteristics. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021266s038,021267s047,021630s028lbl.pdf
- European Medicines Agency (EMA). Vfend, summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vfend
- Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38(Suppl 1):335–347.
- Stella V, He Q. Cyclodestrins. Toxicologic Pathol. 2008;36:30–42.
- Walsh TJ, Pappas P, Winston DJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234.